OBJECTIVE: The objective was to determine the role of arcitumomab ( @entity787 -Scan; Immunomedics, Morris Plains, NJ), an anticarcinoembryonic antigen ( @entity787 ) @entity1334 ' labeled with @entity1136 , in the presurgical evaluation of @entity1 with recurrent or metastatic @entity14 . SUMMARY BACKGROUND DATA: Surgical resection is the only method known to cure recurrent or metastatic @entity14 . The location and extent of disease must be determined before surgery. The role of antibody imaging, a new @entity5 detection modality, in preoperative evaluation for resection of locally recurrent or metastatic @entity14 has not been established, either alone or in combination with standard diagnostic modalities. METHODS: In a blinded analysis of 209 @entity1 with known or suspected @entity14 , the accuracy of arcitumomab, alone and combined with computed tomography (CT), was compared to that of CT for predicting @entity5 resectability by correlating the results with surgical and histopathologic findings. RESULTS: Arcitumomab alone or combined with CT was found to be significantly more accurate for predicting surgical outcome than CT alone. When the results of CT and arcitumomab were concordant for abdominopelvic resectability, nonresectability, or absence of disease, the prediction was accurate in 67%, 100%, and 64%, respectively. Thus, the concordance for nonresectability (100% correct) may obviate the need for other diagnostic modalities or exploratory surgery. When the two tests were discordant, arcitumomab was correct substantially more often than CT. Because the liver is the most common site of distant metastasis in @entity14 , a subset of @entity1 with @entity99 was also analyzed; findings were similar to the overall resectability results. The product's safety profile was excellent: the incidence of induction of an immune response against arcitumomab was <1% and that of potentially adverse events was 1.2%. CONCLUSIONS: The accuracy of arcitumomab for assessing resectability status is greater than that of CT, both in all @entity1 undergoing evaluation for curative abdominopelvic resection of @entity14 and in the subset of @entity1 with suspected or proven liver metastases. The additional use of arcitumomab with CT potentially doubles the number of @entity1 who could be saved the cost, morbidity, and mortality of unnecessary abdominopelvic surgery and increases those who are potentially resectable for cure by 40%.

Use of carcinoembryonic antigen radioimmunodetection and computed tomography for predicting the resectability of recurrent XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1136 :: ('MESH:D013667', 'Chemical') :: ['technetium-99m'] @entity5 :: ('MESH:D009369', 'Disease') :: ['abdominopelvic tumor', 'cancer'] @entity787 :: ('1084', 'Gene') :: ['CEA'] @entity1334 :: ('2187', 'Gene') :: ['Fab'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer', 'colorectal carcinoma'] @entity99 :: ('MESH:D056486', 'Disease') :: ['hepatic disease']
@entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer']
